$ULTA

Cap Stock Picks Poised to Rally in the 2nd Half, According to BofA

BofA analyst Carey Hall said Ulta could rebound in 2H26, keeping a $685 price target despite the stock down 20% YTD on weaker consumer demand. BofA also backed elf Beauty ($85 target) and Wayfair, citing easing supply-chain pressures. It maintained bullish targets for Charles River ($220), Dynatrace, MKS ($2H26 top idea), EastGroup, and Samsara.

Original reporting
Published Jun 26, 2026, 6:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cap Stock Picks Poised to Rally in the 2nd Half, According to BofA — source image
Decision brief

The 30-second read

$ULTABullishLow
01

Why it matters

Because the piece is primarily analyst commentary (targets and narratives) rather than new company disclosures, it is more useful for relative positioning and sentiment than for a fresh fundamental catalyst.

02

Market read

Traders may use the note to adjust relative exposure to the named turnaround/growth stories, but it likely won’t drive a major repricing without new prints.

03

What to watch

Execution risk and timing: turnaround/normalization stories (ULTA/W/EGP) and AI infrastructure demand read-through (DT/MKSI/IOT) can slip if macro conditions or customer capex cycles change.

Relevance 4/10Novelty 3/10Timing: for 2H26 positioning based on BofA’s maintained bullish targets

Background

The article summarizes BofA’s small/mid-cap “cap stock picks” and provides maintained price targets and qualitative theses across multiple companies.

Company-level read

Ticker impact

$ULTABullishMedium confidence
Context

BofA reiterates a bullish view on Ulta, citing a “turnaround is imminent” thesis and maintaining a $685 price target.

Expected impact

Mild upside bias versus peers if traders treat the note as a catalyst; otherwise limited incremental impact.

Evidence & confidence

The article is an analyst call with targets and qualitative rationale, not a fresh earnings/guidance print or operational disclosure.

$ELFBullishMedium confidence
Context

BofA keeps a bullish stance on elf Beauty, maintaining an $85 price target and pointing to margin expansion and tariff rebound benefits.

Expected impact

Moderate sentiment support; likely more relevant for relative-value trades than for a major repricing.

Evidence & confidence

No new financial results are provided—only a maintained target and macro/operational narrative.

$WBullishMedium confidence
Context

BofA sees Wayfair as a likely winner as supply-chain pressures ease, while noting margins near the lower end of its long-term EBITDA range.

Expected impact

Potential modest rebound in sentiment if investors buy into the normalization timing; not a hard catalyst.

Evidence & confidence

The article provides qualitative guidance on what BofA expects, but no new Wayfair-specific print or contract.

$CRLBullishMedium confidence
Context

BofA maintains a bullish view on Charles River Laboratories, keeping a $220 price target despite biotech spending declines.

Expected impact

Limited incremental impact unless traders were underweight on the name; more supportive than directional.

Evidence & confidence

This is target-based commentary without new CRL disclosures.

$DTBullishMedium confidence
Context

BofA highlights Dynatrace as an “industry disruptor,” citing improving fundamentals and AI/digital modernization driving observability usage.

Expected impact

Potential positive bias for growth/AI infrastructure trades; likely gradual rather than immediate repricing.

Evidence & confidence

No new product metrics, bookings, or guidance are disclosed—only an analyst narrative.

$MKSIBullishMedium confidence
Context

BofA names MKS Instruments as its top 2H26 SMID cap idea, expecting WFE capacity expansions and tech upgrades to support AI infrastructure demand.

Expected impact

More likely to influence medium-term positioning than to trigger a near-term fundamental repricing.

Evidence & confidence

The article is a forward-looking analyst thesis with no new MKSI order/backlog or guidance datapoint.

$EGPBullishMedium confidence
Context

BofA stays bullish on EastGroup, citing high demand in the US Sunbelt and ongoing data center buildout support.

Expected impact

Potential modest support for the stock/sector relative to industrial REIT peers if the market buys the tailwind timing.

Evidence & confidence

No new leasing/occupancy or guidance figures are provided—this is primarily an analyst outlook.

$IOTBullishMedium confidence
Context

BofA frames Samsara as a turnaround/growth story, arguing competitive advantages are widening via data scale and platform breadth.

Expected impact

Could help sentiment and reduce perceived downside, but likely not a major catalyst absent new results.

Evidence & confidence

The article provides qualitative competitive claims and expectations rather than fresh company disclosures.

Market effects

Broadly bullish read-through on consumer discretionary retail turnaround (ULTA/ELF), e-commerce normalization (W), and AI infrastructure/observability/industrial tech demand narratives (DT/MKSI/IOT).

EastGroup’s Sunbelt industrial demand framing may reinforce regional industrial REIT sentiment.

Tariff rebound and supply-chain easing assumptions are macro inputs that can affect multiple discretionary and industrial/tech demand expectations.

Counterpoint

These are analyst thesis pieces with maintained targets; without new earnings, guidance, or hard datapoints, the market may already be pricing the turnaround narratives.

Key entities

  • BofA

    Provides bullish price targets and turnaround/growth theses for multiple stocks discussed in the article.

  • Carey Hall

    The named BofA analyst whose written rationale is quoted for several of the picks.

Related articles

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$ELFMedAI 8/10

e.l.f. Beauty Q1 Earnings Call Highlights

e.l.f. Beauty (ELF) reported Q1 gross margin up 1,400 bps to 83%, aided by about $50M in IEEPA tariff refunds, and adjusted EBITDA up 93% to $168M. Adjusted net income rose to $105M, or $1.75/share. The company ended with $344M cash, repurchased $50M stock, and raised FY2027 outlook: adj. EBITDA $401M-$407M and adj. EPS $3.50-$3.55.

$DTHighAI 9/10

Dynatrace Q1 Earnings Call Highlights

Dynatrace (NYSE:DT) reported $309 million in adjusted free cash flow in Q1 and said it changed its FCF definition to exclude certain non-recurring cash expenses. It added 122 new customer logos, with average land size near $285,000 and net retention around 110% (trailing 12 months). Log management grew over 100% to nearly $200 million annualized consumption. Management maintained FY ARR growth outlook (15.5% to 16.5%), raised FY27 revenue growth, and guided non-GAAP EPS to $1.97 to $1.99.

$ELFHighAI 9/10

e.l.f. Beauty Announces First Quarter Fiscal 2027 Results

e.l.f. Beauty reported first quarter fiscal 2027 results for the three months ended June 30, 2026. Net sales rose 36% to $479.4 million, with growth attributed to retailer and e-commerce channels. GAAP net income was $66.6 million and adjusted net income $104.6 million. The company raised its fiscal 2027 net sales outlook to 18% to 20% growth.

$DTMed

Dynatrace, Inc. Q1 2027 Earnings Call Summary

Dynatrace reported Q1 2027 results on an earnings call, citing 66% net new ARR growth, driven by go-to-market changes and record new logo growth. Log management consumption neared a $200M annualized run rate. Management reiterated high-conviction FY27 ARR acceleration, citing a $14M FX ARR headwind and $4M revenue headwind, plus a $275M Q1 share repurchase. CFO Jim Benson plans to retire by fiscal year-end.

$CRLMed

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.